Research has shown that benign prostatic hyperplasia (BPH) is the most common non-cancerous neoplasm (tissue growth or tumor) among American men. BPH, a chronic condition associated with increasing lower urinary tract symptoms, affects nearly 3 out of 4 men in their 70’s. In addition, approximately 15% of all men suffer from symptoms of prostatitis (inflammation of the prostate) at some point d...

Early localization of biochemical recurrence in patients after radical treatment of prostate cancer is a widely accepted clinical indication of (11)C-choline PET/CT. Its widespread clinical use has prompted the depiction of incidentalomas, unusual sites of metastatic lesions, as well as false positive and negative cases. Over the last 6 years, a total of 454 (11)C-choline PET/CT studies have be...

Introduction: All men show characteristics of benign prostatic hyperplasia (BPH) upon aging; it is the most common benign neoplasm in men. When the prostate is enlarged it causes a narrowing of the urethra leading to bladder outlet obstruction and reduced urine flow. The symptoms vary and include nocturia, incomplete emptying, urinary hesitance, weak stream, urgency and frequency to the develop...

BACKGROUND Tumor angiogenesis is an absolute requirement for tumor growth and a prognostic factor for various malignant neoplasms. Recent reports in the literature have addressed the importance of the VEGF system in benign prostatic hyperplasia (BPH) and adenocarcinoma, however the results are controversial. The aim of the present study was to determine and compare the levels of VEGF expression...

The appearance of several unusual tumours in the prostate has resulted in questions being raised concerning their histogenesis; moreover, some of these tumours have prognoses that are quite unlike those of prostatic adenocarcinoma. Unusual neoplasms involving the prostate have been described in recent years, including mucinous cystadenocarcinoma, neuroendocrine cancer, lymphoma, spindle cell ne...

The surgical specimens from 51 men submitted to radical prostatectomy for localized prostate cancer were examined by immunohistochemistry using proliferation cell nuclear antigen (PCNA) monoclonal antibody to evaluate the proliferative index (PI). The relationship between PI, biological variables and p53 protein expression was evaluated by immunohistochemistry. PI was low in invasive localized ...

Prostate cancer treatment is currently based on surgical removal, radiotherapy, and hormone therapy. In recent years, another therapeutic method has emerged-immunological treatment. Immunotherapy modulates and strengthens one's immune responses against cancer. Neoplastic cells naturally escape from the control of the immune system, and the main goal of immune therapy is to bring the control bac...

Objective. Prostate cancer is currently the most frequently diagnosed malignant neoplasm and the second leading cause of cancer related mortality in men over the age of 50 years in the developed countries. MicroRNA-33a (miR-33a), localized within the intron 16 of SREBF2, has been reported to have tumor suppressive properties in some cancers including prostate cancer, whereas its host gene, SREB...

Orbital metastasis is a rare occurrence found only in about 3 - 10% of all prostate cancers. A 72 years male presented with proptosis of the left eye associated with pain, blurred vision and frequent headaches for the past 8 months. Past medical history had symptoms of bladder outflow obstruction for 3 years. MRI brain and orbit with contrast was consistent with a large soft tissue mass in the ...